The share buyback trend in the Hong Kong stock market has continued into 2026, with leading companies remaining the primary drivers. These firms consistently use repurchases to signal confidence in their intrinsic value and future growth prospects. YIDU TECH is a prominent example in the AI healthcare sector. On February 16, YIDU TECH announced another share repurchase: the company bought back 404,000 shares at approximately HK$5.91 per share, totaling nearly HK$2.4 million. This marks the 15th repurchase conducted by the company since the start of 2026, maintaining a frequent repurchase pattern initiated on January 26. The cumulative expenditure has now reached close to HK$67 million.

Examining its buyback activity in 2026, YIDU TECH's strategy is characterized by high frequency and consistent intensity. Since commencing its first repurchase of the year on January 26, the company has executed 15 buybacks in less than a month, demonstrating a persistent and determined approach.

Positive business developments provide further support. Recently, a multi-modal AI database project for gastrointestinal cancer diagnosis and treatment, jointly submitted by YIDU TECH and Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, was successfully selected for the National Ministry of Industry and Information Technology's 2025 "Unveiling the List" initiative for innovative AI medical device tasks.

Furthermore, YIDU TECH's growth prospects have gained institutional endorsement. In February, Citi issued a research report maintaining its "Buy" rating on YIDU TECH and raised its target price to HK$11.